New hope for rare gut cancer: drug showdown after standard therapy fails
Disease control
Completed
This study tested a new drug called ripretinib against an older drug, sunitinib, in 108 people with advanced gastrointestinal stromal tumors (GIST) whose cancer had stopped responding to the first-line treatment imatinib. The goal was to see which drug better delays cancer growth…
Phase: PHASE2 • Sponsor: Zai Lab (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 13, 2026 16:00 UTC